BRAF and non-small cell lung carcinoma: The efficacy of adjuvant targeted therapy in ALK fusion and EGFR mutation NSCLC has been demonstrated, while the effectiveness of perioperative targeted therapy for BRAF V600E NSCLC remains uncertain.